The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
Data from MMRF's Immune Atlas will be included in its recently launched CureCloud, a registry of clinical, genomic, and EHR data from multiple myeloma patients.
A structural variant analysis based on genome sequences for almost 800 multiple myeloma cases suggests a IgL translocation present in nearly 10 percent of patients may inform survival.
Following FDA approval last October, Adaptive has now secured Medicare coverage for its NGS-based minimal residual disease assay, ClonoSeq.
Mayo Clinic researchers found that cytogenetic subtypes containing three translocations were more common in individuals with a greater proportion of African ancestry.
In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.
These and previously uncovered multiple myeloma risk loci may influence disease by affecting developmental transcriptional regulators.
The platform integrates whole exome and RNA sequencing for downstream RNA-based drug repurposing to treat patients with relapsed multiple myeloma.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.
The University of California, Berkeley's Jennifer Doudna reflects at Science on the anniversary of the announcement of the birth of twin girls who underwent genome editing.
By studying its enamel proteome, researchers have found the ancient ape Gigantopithecus blacki belongs to a sister clade to that of orangutans.
Bloomberg Businessweek discusses genomics with BGI's Wang Jian.
In Science this week: researchers find transplanting the gut microbiome in mice affects physiology, and more.